Treatment of psoriasis with etanercept: An experience from South Kuwait

Al-Abdulrazzaq, Adel; Zadeh, Valid Bagher; Al-Otaibi, Sultan; Tarrab, Sahar; Najem, Nabeel
April 2012
Journal of Pakistan Association of Dermatologists;2012, Vol. 22 Issue 2, p136
Academic Journal
Objective To observe the efficacy and safety profile of etanercept in patients with moderate to severe plaque psoriasis. Patients and methods In this retrospective study, 56 patients were treated with etanercept between May 2005 and May 2008. All patients were screened for tuberculosis. They were started on etanercept 50 mg twice a week (BIW) for 12 weeks followed by 25 mg BIW for another 12 weeks. Response to treatment was assessed by Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI). Patients were reviewed at 4-week intervals, when clinical response and adverse effects were noted and photographs taken. Results Forty-nine patients (87.5%) had chronic plaque psoriasis, three (5.35%) were erythrodermic and four (7.15%) had palmoplantar psoriasis. At least 75% reduction in PASI was achieved in 52% of patients at week 12 and 64% at week 24. Mean percentage of improvement from baseline in DLQI at week 12 was 47.6%, reaching 79% at week 24. The percentage of patients in the DLQI category correlating with 'no effect' on quality of life increased from 3.6% at baseline to 66% at week24, while the percentage in the category correlating with 'extremely large effect' decreased from 16% at baseline to 1.8% at week 24. In our study, a correlation was noted between DLQI and PASI score before treatment as well as at week 12 and 24. The adverse effects and laboratory abnormalities were minor. Conclusions Etanercept was effective and well tolerated for moderate to severe psoriasis. It can be used intermittently without rebound, with psoriasis responding again on reintroduction.


Related Articles

  • Relation of physician specialty and HIV/AIDS experience to choice of guideline-recommended antiretroviral therapy. Stone, Valerie E.; Mansourati, Fadi F.; Poses, Roy M.; Mayer, Kenneth H.; Stone, V E; Mansourati, F F; Poses, R M; Mayer, K H // JGIM: Journal of General Internal Medicine;Jun2001, Vol. 16 Issue 6, p360 

    Background: Controversy exists regarding who should provide care for those with HIV/AIDS. While previous studies have found an association between physician HIV experience and patient outcomes, less is known about the relationship of physician specialty to HIV/AIDS outcomes or...

  • Etanercept of value in rheumatoid arthritis.  // PharmacoEconomics & Outcomes News;6/2/2007, Issue 529, p1 

    The article presents information on the results of two studies from Great Britain which found that etanercept is more cost effective than rituximab for the treatment of rheumatoid arthritis (RA). Sequential Monte Carlo models were developed to estimate the lifetime costs and outcomes of...

  • Etanercept is Not Harmful.  // Fertility Weekly;1/14/2002, p17 

    Describes the first case of ovulation induction, intrauterine insemnation, normal pregnancy and singleton delivery of a healthy infant following chronic pre-ovulatory tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis. Existence of a theoretical risk; Confirmation of a...

  • Head of the class. Petrou, Ilya // Dermatology Times;Apr2011 Easing The Angst Supplement, p30 

    The article discusses the effectiveness of etanercept in treating scalp psoriasis, as being noted in a placebo controlled, double-blind study. It says that adult patients with moderate to severe plaque psoriasis were randomized to receive etanercept and placebo. It cites that the study showed...

  • American College of Rheumatology.  // BioWorld Today;10/21/2009, Vol. 20 Issue 203, p3 

    The article reports that Abbott of Abbott Park, Illinois, has shown data that Humira (adalimumab) plus methostrexate decreased progression of rheumatoid arthritis and joint swelling and tenderness after eight years of treatment. It is stated that Humira is an approved treatment for rheumatoid...

  • Etanercept Reduces Symptoms and Severity of Psoriasis After Cessation of Cyclosporine Therapy: Results of the SCORE Study. MICALI, Giuseppe; WILSMAN-THEIS, Dagmar; MALLBRIS, Lotus; GALLO, Gaia; MARINO, Valentina; BRAULT, Yves; GERMAIN, Jean-Michel // Acta Dermato-Venereologica;Jan2015, Vol. 95 Issue 1, p57 

    Cyclosporine is an established therapy for psoriasis that provides rapid relief of symptoms but has longterm toxic side effects. The objective of this study was to demonstrate the efficacy of etanercept as replacement therapy for cyclosporine in patients with moderate-tosevere plaque psoriasis....

  • Eficacy and Safety of Systemic Treatments for Psoriasis in Elderly Patients. PIASERICO, Stefano; CONTI, Andrea; LO CONSOLE, Francesco; DE SIMONE, Clara; PRESTINARI, Francesca; MAZZOTTA, Annamaria; GUALDI, Giulio; GUARNERI, Claudio; BORSARI, Stefania; CASSANO, Nicoletta // Acta Dermato-Venereologica;May2014, Vol. 94 Issue 3, p293 

    Management of psoriasis in elderly patients can be chalenging, because of the impairment of immune system eficiency and the presence of comorbidities that contraindicate systemic therapies. We studied the safety and eficacy of systemic traditional and biological treatments in 187 consecutive...

  • Pediatric Rheumatology.  // Current Medical Literature: Rheumatology;2010, Vol. 29 Issue 1, p18 

    The article deals with two studies concerning pediatric rheumatology. The first study examined the long-term safety and efficacy of etanercept in children with selected categories of juvenile idiopathic arthritis, published in a 2009 issue of "Arthritis & Rheumatology." The second study, which...

  • Not all vitamins are safe. Wong, H. C. George // British Columbia Medical Journal;Mar2014, Vol. 56 Issue 2, p82 

    A letter to the editor is presented related to harmful effects of vitamins as in the case of disease-modifying antirheumatic drug (DMARD).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics